AI assistant
Sintx Technologies, Inc. — Regulatory Filings 2017
May 16, 2017
35101_rns_2017-05-16_a492b85c-03d5-4d1c-973f-ddfb7fae2d5b.zip
Regulatory Filings
Open in viewerOpens in your device viewer
NT 10-Q 1 nt10-q.htm
Field: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File Number: 001-33624
CUSIP Number: 023435209
(Check one:) [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR
For Period Ended: March 31, 2017
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ______________
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not applicable
PART I - REGISTRANT INFORMATION
| Full Name of Registrant: | Amedica Corporation | | --- | --- | | Former Name if applicable: | | | Address of Principal Executive Office: | 1885 W 2100 S | | | Salt Lake City, UT 84119 |
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
PART II - RULE 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed: (Check box if appropriate)
| [X] | (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; | | --- | --- | --- | | [ ] | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | | [ ] | (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, NCSR, or the transition report or portion thereof, could not be filed within the prescribed period.
Amedica Corporation (the “Company”) has not yet completed certain financial and other information necessary for an accurate and full completion of the Quarterly Report. As a result, the Company cannot, without unreasonable effort or expense, file its Form 10-Q on or prior to the prescribed due date.
PART IV - OTHER INFORMATION
| (1) |
|---|
| David |
| Truetzel, Audit Committee Chairman (314) 448-1316 |
| (2) |
|---|
| The |
| Company has not filed its Annual Report on Form 10-K for the fiscal year ending December 31, 2016. |
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Field: Page; Sequence: 2
Field: /Page
Amedica Corporation has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| /s/
| B. Sonny Bal |
|---|
| B. |
| Sonny Bal, MD |
| CEO |
| and President |
Field: Page; Sequence: 3
Field: /Page